title: Development of monoclonal antibodies for therapeutic drug monitoring.
abstract: For the development of multilayer fluorescent immunoassays to determine directly a variety of therapeutic drugs high specific monoclonal antibodies against the anticonvulsants carbamazepine, phenobarbital, phenytoin and valproic acid have been prepared. For each antibody a standard curve could be established showing good linearity and a suitable sensitivity scope. To validate the eligibility of the desired antibodies a variety of drugs and metabolites sharing structural similarities to the individual drugs were tested for their cross-reactivity. It could be shown that only a few very closely related compounds exhibited substantial cross-reactivity. These monoclonal antibodies are therefore assumed to be suitable for a TDM-assay development.
authors: Research Laboratories, Behringwerke AG, Marburg, W.-Germany.
authors: G
authors: G
authors: Walter
authors: K
authors: K
authors: Grün
authors: M
authors: M
authors: Siebert
authors: S
authors: S
authors: Bausch
authors: S
authors: S
authors: Gassmann
authors: B
authors: B
authors: Löchel
authors: R
authors: R
authors: Kreider
authors: J
authors: J
authors: Blackwood
authors: S
authors: S
authors: Inbar
mesh_terms: D000911:Antibodies, Monoclonal; D000927:Anticonvulsants / Q000097:blood*; D002220:Carbamazepine / Q000097:blood; D003429:Cross Reactions; D006801:Humans; D008991:Monitoring, Physiologic / Q000379:methods; D010634:Phenobarbital / Q000097:blood; D010672:Phenytoin / Q000097:blood; D011324:Primidone / Q000097:blood; D014635:Valproic Acid / Q000097:blood
chemical_list: D000911:Antibodies, Monoclonal; D000927:Anticonvulsants; D011324:Primidone; D002220:Carbamazepine; D014635:Valproic Acid; D010672:Phenytoin; D010634:Phenobarbital